Roivant Sciences (NASDAQ:ROIV) Given Buy Rating at HC Wainwright

Roivant Sciences (NASDAQ:ROIV)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $18.00 target price on the stock. HC Wainwright’s target price indicates a potential upside of 71.02% from the stock’s current price.

Separately, Cantor Fitzgerald raised Roivant Sciences to a “strong-buy” rating in a report on Thursday, January 30th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Roivant Sciences presently has a consensus rating of “Buy” and a consensus price target of $17.93.

Roivant Sciences Stock Performance

Shares of Roivant Sciences stock traded down $0.27 on Tuesday, hitting $10.53. 2,308,625 shares of the company traded hands, compared to its average volume of 4,178,285. Roivant Sciences has a 52 week low of $9.76 and a 52 week high of $13.06. The business has a 50-day simple moving average of $11.51 and a 200 day simple moving average of $11.60. The stock has a market capitalization of $7.66 billion, a P/E ratio of 1.87 and a beta of 1.25.

Roivant Sciences (NASDAQ:ROIV) last released its quarterly earnings data on Monday, February 10th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a net margin of 3,827.42% and a negative return on equity of 14.65%. Research analysts expect that Roivant Sciences will post -1.19 earnings per share for the current year.

Insiders Place Their Bets

In other Roivant Sciences news, COO Eric Venker sold 100,000 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $11.28, for a total transaction of $1,128,000.00. Following the transaction, the chief operating officer now owns 732,294 shares of the company’s stock, valued at approximately $8,260,276.32. This trade represents a 12.01 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Sciences Ltd. Roivant bought 16,845,010 shares of the stock in a transaction on Monday, January 13th. The shares were bought at an average price of $20.00 per share, with a total value of $336,900,200.00. Following the acquisition, the director now owns 96,650,341 shares of the company’s stock, valued at $1,933,006,820. This trade represents a 21.11 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold 1,942,629 shares of company stock valued at $23,034,486 over the last three months. 7.90% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. TOMS Capital Investment Management LP bought a new stake in shares of Roivant Sciences in the 3rd quarter valued at about $46,333,000. FMR LLC increased its position in Roivant Sciences by 5.6% during the 3rd quarter. FMR LLC now owns 49,145,056 shares of the company’s stock valued at $567,134,000 after buying an additional 2,593,910 shares in the last quarter. Geode Capital Management LLC raised its stake in Roivant Sciences by 23.2% in the third quarter. Geode Capital Management LLC now owns 7,745,104 shares of the company’s stock valued at $89,400,000 after buying an additional 1,460,205 shares during the last quarter. State Street Corp boosted its holdings in Roivant Sciences by 6.1% in the third quarter. State Street Corp now owns 19,561,249 shares of the company’s stock worth $225,737,000 after acquiring an additional 1,118,561 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Roivant Sciences by 49.4% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,307,178 shares of the company’s stock worth $26,625,000 after acquiring an additional 762,953 shares during the last quarter. 64.76% of the stock is currently owned by hedge funds and other institutional investors.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.